<A >prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0104042" target="_blank" >RIV/00843989:_____/13:E0104042 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1747-4949.2012.00901.x" target="_blank" >http://dx.doi.org/10.1111/j.1747-4949.2012.00901.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1747-4949.2012.00901.x" target="_blank" >10.1111/j.1747-4949.2012.00901.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

<A >prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke

Popis výsledku v původním jazyce

Background The neurotrophic drug Cerebrolysin accelerated recovery and prevented acute neuronal damage in preclinical models of ischaemia. Previous clinical trials support therapeutic effects in stroke patients. The study investigated whether the combination with alteplase and Cerebrolysin is safe and can further reduce disability after acute ischaemic stroke. Methods This placebo-controlled, double-blind trial involved 119 patients with acute ischaemic hemispheric stroke, randomly assigned to a combined treatment with alteplase plus Cerebrolysin or placebo (administered 1?h after thrombolytic treatment) starting within three-hours after onset of symptoms. A daily i.v. infusion of 30?ml Cerebrolysin or placebo was given for 10 consecutive days. Primaryoutcome was the modified Rankin Scale at day 90. A sequential design with interim analyses was applied. Results The third interim analysis did not show a benefit in the modified Rankin Scale for Cerebrolysin on day 90 compared to placebo

Název v anglickém jazyce

<A >prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke

Popis výsledku anglicky

Background The neurotrophic drug Cerebrolysin accelerated recovery and prevented acute neuronal damage in preclinical models of ischaemia. Previous clinical trials support therapeutic effects in stroke patients. The study investigated whether the combination with alteplase and Cerebrolysin is safe and can further reduce disability after acute ischaemic stroke. Methods This placebo-controlled, double-blind trial involved 119 patients with acute ischaemic hemispheric stroke, randomly assigned to a combined treatment with alteplase plus Cerebrolysin or placebo (administered 1?h after thrombolytic treatment) starting within three-hours after onset of symptoms. A daily i.v. infusion of 30?ml Cerebrolysin or placebo was given for 10 consecutive days. Primaryoutcome was the modified Rankin Scale at day 90. A sequential design with interim analyses was applied. Results The third interim analysis did not show a benefit in the modified Rankin Scale for Cerebrolysin on day 90 compared to placebo

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International journal of stroke

ISSN

1747-4930

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

n. 2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

"p. 95-104"

Kód UT WoS článku

000313880700008

EID výsledku v databázi Scopus

—